A possible explanation as to why we observed no increase in bone formation markers in non-responding patients, despite a direct positive effect of bortezomib on osteoblasts precursors, could be that a continued high myeloma tumor burden resulted in high levels of osteoblast inhibitors e.g. DKK-1 abrogating any such effect. The gene discussed is DKK1; the disease is neoplasm.